What is the size of the Aldagen IPO?
As of now, the exact size of Aldagen IPO is not known, but as per the indications from the SEC filings, the company may float the Aldagen IPO with the aim of raising capital to the tune of around 80.5 million USD. The numbers are only indicative for the filing purpose and may change late.
What is the expected price range of the Aldagen IPO?
No information is available about the expected Aldagen IPO.
What are the market standings and product details of the Aldagen IPO company?
Aldagen has four product candidates in clinical trials consisting of adult stem cells, which are found in blood, tissues and organs and can potentially develop into other types of cells.
The most advanced product candidate, which is in late stage trials, is designed to improve umbilical cord blood transplants used to treat children with inherited and degenerative metabolic diseases. Cord blood from donor banks is often used when bone marrow from a close relative of the patient is not available.
What are the financial results and business valuations of the Aldagen IPO?
The news does not sound very promising when one looks at the recent past results of Aldagen IPO. In 2007, the company reported a net loss of $6.7 million.
Where will the capital raised be used by the Aldagen IPO?
Aldagen plans to use the proceeds of its IPO to expand its research and development activities, to improve its manufacturing processes, to commercialize its product candidates and for general corporate purposes.
Who are the lead underwriters of the issue?
Cowen and Co., Wachovia Capital Markets and Pacific Growth Equities are underwriting the IPO.
| Which ticker symbol will be used by Aldagen IPO shares? Aldagen plans to list its shares on the Nasdaq Global Market under the symbol "ALDH." Let’s see how this IPO performs once its lists on the stock exchanges. | Table of Contents |
No comments:
Post a Comment